CJC-1295 (No DAC) + Ipamorelin: The Growth Hormone Pulse Research Guide

What is the CJC-1295 and Ipamorelin blend?

The CJC-1295 and Ipamorelin blend combines two research peptides that act on the growth hormone axis through different receptors. CJC-1295 (No DAC), also known as Modified GRF (1-29), is a growth hormone releasing hormone (GHRH) analogue studied for its action at the GHRH receptor on the pituitary. Ipamorelin is a highly selective growth hormone secretagogue that acts as a ghrelin mimetic at the ghrelin receptor (GHS-R1a). Supplied together in a single vial, the pair is the classic GHRH-plus-secretagogue combination that endocrinology researchers keep returning to when they model pulsatile growth hormone secretion.

This combination is one of the most studied and most requested growth hormone research pairings, because each peptide drives GH release through a separate mechanism at the same time. Throughout this guide the blend is discussed only as a research compound. It is not approved by the Therapeutic Goods Administration or any regulator, and NovaPeptides supplies it for laboratory research use only, not for human consumption. What can be stated with confidence is provenance and transparency: an Australian-owned supplier that has served researchers here for over three years, with a verifiable Novagen Certificate of Analysis on every batch.

The two components explained: CJC-1295 (No DAC) and Ipamorelin

The blend works because the two peptides belong to different pharmacological classes that converge on the same target cell. Understanding each component separately is the clearest way to understand why they are studied together.

CJC-1295 (No DAC), also known as Modified GRF (1-29)

• A synthetic analogue of the first 29 amino acids of growth hormone releasing hormone, the fragment credited with the full activity of native GHRH.
• Carries four amino acid substitutions that increase resistance to enzymatic breakdown by the DPP-IV enzyme, improving stability compared with unmodified sermorelin.
• The No DAC designation means it is supplied without the Drug Affinity Complex, the albumin-binding moiety that greatly extends half-life. Without it, the peptide is short-acting.
• Reported in the literature to have a short half-life, in the order of about thirty minutes, which is why it is characterised as producing a sharp GH pulse rather than a sustained baseline elevation.
• Acts at the GHRH receptor on the somatotroph cells of the anterior pituitary, the same receptor family targeted by native GHRH.

Ipamorelin

• A selective pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.
• Acts as a ghrelin mimetic, binding the growth hormone secretagogue receptor (GHS-R1a) rather than the GHRH receptor.
• Noted in research for its selectivity. It prompts growth hormone release with minimal reported involvement of cortisol, prolactin or ACTH, which distinguishes it in the literature from earlier secretagogues such as GHRP-6 and GHRP-2.
• Reported to have a longer half-life than CJC-1295 (No DAC), in the order of about two hours in published pharmacology.
• Because it works through a separate receptor, it is frequently paired with a GHRH analogue in growth hormone research models.

Mechanism of action and receptor targets

The two peptides target two distinct receptors that both sit on the somatotroph, the growth hormone producing cell of the anterior pituitary. CJC-1295 (No DAC) binds the GHRH receptor, a G-protein coupled receptor that signals through the cAMP pathway to drive the synthesis and release of growth hormone. Ipamorelin binds the ghrelin receptor GHS-R1a, which signals through a phospholipase C and calcium-dependent pathway. Ghrelin receptor activation is also studied for its ability to suppress somatostatin tone, and somatostatin is the hormone that normally brakes growth hormone release.

Because the GHRH pathway and the ghrelin pathway are independent, activating both at once is studied for an amplified pituitary response. The GHRH signal raises the amount of growth hormone available to be released, while the ghrelin mimetic amplifies the size of the pulse and dampens the somatostatin brake. This dual mechanism is exactly why the combination is used as a research model of pulsatile growth hormone secretion rather than either peptide on its own.

What the blend is studied for in research

In research settings, the CJC-1295 and Ipamorelin combination is used to investigate the growth hormone axis and its downstream signalling. The areas below describe what the compounds are studied for in the literature and in laboratory models. They are not claims about outcomes in people.

• Pulsatile growth hormone secretion and the dynamics of the GH axis, including pulse amplitude and frequency.
• Downstream IGF-1 signalling, since growth hormone drives insulin-like growth factor 1 production in the liver.
• Somatotroph physiology and receptor pharmacology, comparing the GHRH receptor and GHS-R1a pathways.
• Body composition research models, where growth hormone signalling and its metabolic effects are of interest.
• Recovery and tissue research models that examine growth hormone and IGF-1 in repair processes.
• The relationship between sleep and growth hormone pulses, given that GH release is concentrated in slow-wave sleep.
• Age-related decline in growth hormone output, sometimes called somatopause, as a model of the ageing endocrine system.

Each of these is an area of scientific investigation. The presence of a research area on this list is not a statement that the blend produces any particular result, and it is not a suggestion of use by any person.

The research landscape and what the literature shows

The idea behind this blend rests on decades of growth hormone endocrinology. GHRH itself was characterised in the early 1980s, and sermorelin, the GHRH(1-29) fragment, established that a short peptide could reproduce the activity of the full hormone. Ghrelin, the natural ligand of the GHS-R1a receptor, was identified in 1999, which explained how a separate class of secretagogues could stimulate growth hormone release. Ipamorelin was first described in the late 1990s and stood out in that work for releasing growth hormone with far less effect on cortisol and prolactin than the secretagogues that came before it. CJC-1295 was developed as a stabilised GHRH analogue, and the No DAC form is the short-acting version studied for pulse-like signalling.

The rationale for combining a GHRH analogue with a secretagogue is well documented. Studies that co-administer GHRH with a growth hormone releasing peptide consistently report a greater growth hormone response than either agent alone, which is the synergy the blend is built around. It is important to be clear about the limits of this evidence. Much of the specific data on these peptides is preclinical or comes from early human pharmacology studies of the individual compounds, and neither peptide, nor the blend, is an approved therapy. That is precisely why the compounds sit in the research space rather than the clinical one.

How the blend is handled in a laboratory context

The points below describe how peptides of this kind are handled as laboratory materials by qualified researchers. They are stability and storage considerations, not instructions for use by any person.

• The blend is supplied as a lyophilised (freeze-dried) powder, the stable form in which research peptides are shipped and stored.
• In a laboratory, reconstitution is typically performed with bacteriostatic water so the peptide can be worked with as a solution.
• The lyophilised powder is generally stored cold, and once reconstituted the solution is kept refrigerated, as peptides in solution are less stable than the dry powder.
• Repeated freeze and thaw cycles are avoided because they can degrade peptide integrity, so aliquoting is common practice.
• A cold chain during transit and correct storage on arrival help preserve purity and the reproducibility of any work.
• Accurate labelling, batch records and documentation are part of sound laboratory handling and support traceability back to the Certificate of Analysis.

Sourcing, purity and the Certificate of Analysis

For any peptide research, purity is the foundation of reproducibility. Impurities, truncated sequences or the wrong peptide content can quietly undermine a study before it begins, which is why serious research sourcing centres on independent analysis rather than a supplier's word. A Certificate of Analysis (COA) is the document that records what independent testing found for a specific batch.

What a peptide Certificate of Analysis typically covers

• Identity, usually confirmed by mass spectrometry against the expected molecular weight of each peptide in the blend.
• Purity, usually measured by high performance liquid chromatography (HPLC) and expressed as a percentage.
• Peptide content or net peptide, which reflects how much of the vial contents is actually peptide.
• Appearance and physical description of the lyophilised material.
• The batch or lot number, so the certificate can be matched to the exact vial supplied.

NovaPeptides supplies the CJC-1295 and Ipamorelin blend with a verified Novagen Certificate of Analysis on every batch, and each certificate can be checked on the laboratory's own register before any work begins. That means the purity of the specific batch is documented and independently verifiable, rather than assumed.

Why researchers choose NovaPeptides

When Australian researchers source growth hormone research peptides, the questions that matter are provenance, purity and consistency. NovaPeptides is built around answering all three plainly.

• Australian owned and Gold Coast based, so orders are handled locally rather than shipped in from an unknown overseas source.
• Over three years supplying research peptides to Australian researchers, with the consistency that a long track record brings.
• A verified Novagen Certificate of Analysis on every batch, checkable on the lab register, so purity is documented for the exact batch supplied.
• Clear research-use-only positioning, with no medical or performance claims and no dosing guidance, in line with how research materials should be supplied.
• The CJC-1295 and Ipamorelin blend is one of the most requested growth hormone research pairings NovaPeptides carries, alongside the single-compound CJC-1295 (No DAC) and Ipamorelin for researchers who prefer to work with each peptide separately.

Research use status in Australia

The CJC-1295 and Ipamorelin blend is not approved by the Therapeutic Goods Administration for human use, and it is not an approved medicine or therapy in Australia. It is supplied strictly for laboratory and research use only, and it is not for human consumption. It should be handled only by qualified researchers in an appropriate research setting, in line with all applicable laws and institutional requirements.

Frequently asked questions

Related guides